PT-141
Bremelanotide · PT-141
PT-141 (bremelanotide) is a synthetic peptide studied in in-vitro and preclinical research as a melanocortin-receptor agonist (MC1R/MC4R). Research reagent only — not for human consumption.
Key facts
- Class
- Melanocortin analogue
- Targets
- MC1R / MC4R
- Form
- Lyophilised (powder)
- Status
- Research Use Only
Study library
All results on PubMedPT-141 Palatin.
Hedlund P · Current opinion in investigational drugs (London, England : 2000) · 2004
Bremelanotide.
— · 2012
Bremelanotide (Vyleesi) for hypoactive sexual desire disorder.
— · The Medical letter on drugs and therapeutics · 2019
Bremelanotide.
— · 2006
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.
Nelson ME, et al. · Clinical toxicology (Philadelphia, Pa.) · 2012
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.
Cipriani S, et al. · Expert opinion on pharmacotherapy · 2023
Bremelanotide: First Approval.
Dhillon S, et al. · Drugs · 2019
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.
Pettigrew JA, et al. · Journal of midwifery & women's health · 2021
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
Renke G, et al. · International journal of molecular sciences · 2026
Pharmacologic therapeutic options for sexual dysfunction.
Burton CS, et al. · Current opinion in obstetrics & gynecology · 2022
Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
Borland JM, et al. · Neuropharmacology · 2025
Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis.
Weinberger JM, et al. · Obstetrics and gynecology · 2018
Results retrieved live from PubMed (NCBI). Research literature only — no medical advice.
Research peptides — Research Use Only
- Not for human consumption
- Not for the diagnosis, treatment or prevention of any disease